Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease.

Battaglia Parodi, M; Munk, Marion; Iacono, P; Bandello, F (2015). Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease. British journal of ophthalmology, 99(9), pp. 1268-1270. BMJ Publishing Group 10.1136/bjophthalmol-2014-305783

Text 1268.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (459kB) | Request a copy

INTRODUCTION:

To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularisation (CNV) associated with Stargardt disease.

METHODS:

Prospective, interventional, case series. All patients underwent intravitreal ranibizumab injections following a pro re nata regimen with monthly examination, over a 24-month follow-up.

RESULTS:

Three eyes were included in the study. Best corrected visual acuity changed from 0.47±0.06 (mean±SD) at baseline to 0.90±0.17 LogMAR at the end of the 24-month follow-up. Overall, a mean number of 11 ranibizumab injections were administered in 24 months. Significant atrophic growth was detected in all cases, with the mean atrophy area increasing from 2.34±2.60 mm(2) (mean±SD) at baseline to 4.23±3.31 mm(2) at the end of the follow-up.

CONCLUSIONS:

Ranibizumab treatment can stop the CNV progression, but cannot ensure a significant visual improvement. Macular atrophy tends to significantly enlarge under ranibizumab treatment over the follow-up.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Interest & Impact

Downloads

1 since deposited on 12 Apr 2016
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item